Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relative Bioavailability of Four Alternative Oral Formulations Versus the Current Tablet Formulation of Lapatinib.

Next Previous
Trial Profile

Relative Bioavailability of Four Alternative Oral Formulations Versus the Current Tablet Formulation of Lapatinib.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Cancer
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 15 Feb 2015 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
  • 12 Oct 2008 Status changed from discontinued to suspended as reported by ClinicalTrials.gov.
  • 02 Sep 2008 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top